ANGLE plc, a liquid biopsy company, participated in the 6th Advances in Circulating Tumor Cells (ACTC) conference in Greece. The conference focused on the latest developments and clinical applications of liquid biopsy and precision oncology. ANGLE presented nine posters showcasing its Parsortix® system in six cancer types across eight independent study centers. The posters highlighted various findings, including the relevance of CTC biomarkers for monitoring treatment response in Non-Small Cell Lung Cancer (NSCLC), the clinical significance of mesenchymal CTCs in lung, pancreatic, and bone cancer, and the dual analysis of CTCs and ctDNA. ANGLE received positive feedback on the Parsortix system and plans to expand its translational research use through international distributors while growing its biopharma services business.